The Hyderabad-based Bioserve Clinical Research, in which the US headquartered QPS recently picked up a majority stake, is all set to capitalize on its association with the US firm.

According to the company, the association with QPS will enable it to offer more services to its customers. It is hoping to bag more number of phase II and phase III studies in the coming days as it is equipped with the advantage of providing trials in various regions to its clients because of the presence of QPS in several countries.

Speaking to Pharmabiz, Suneil S Reddy, managing director, Bioserve Clinical Research (P) Ltd, said, “The association with QPS will enable us to offer first in-human trials to our Indian customers outside the country because of the presence QPS in various regions. Unless the CROs have presence in various regions it would be difficult for them as the pharma companies want to carry out trials of their drugs in various regions.”

The company, which has conducted over 500 studies over the past six years, is hoping to host more than 100 studies, mainly bioequivalence studies in the next one year. It said that 60 to 70 per cent of its clients are leading domestic companies and foreign companies form the remaining client list. The company was also inspected by the US Food and Drug Administration (US FDA), the UK Medicines and Healthcare Products Regulatory Agency (UK MHRA), World Health Organisation (WHO) and Drugs Controller General of India (DCGI) in the past.

Reddy added that the company, with 130 employees, is growing at the pace of 40 per cent since its inception in 2005. Bioserve, engaged in providing world-class clinical research services to companies across the globe, have a bed-capacity of 92-beds for conducting trials. The firm’s bioanalytical lab is equipped with multiple LC/MS systems for small molecule bioanalysis.

As per the agreement between the two companies, the current management team headed by Suneil Reddy will continue to manage operations of Bioserve. The bed capacity of QPS has increased to 400 beds with the picking up of majority stake in Bioserve. QPS has its bioanalysis and preclinical testing facilities in the US, the Netherlands and Taiwan and early-phase clinical facilities in the US, Taiwan and Netherlands.